Table 4.
Effect of preventive steroid therapy after total circumferential endoscopic submucosal dissection for esophageal squamous cell carcinoma.
| Author | Year | Study Design | Drugs | Dose | Timing of Intervention | Incidence of Stricture |
|---|---|---|---|---|---|---|
| Steroid injection | ||||||
| Yamaguchi [33] | 2013 | Retrospective | TA | 80 mg | Day 0, 21 | 100% (4/4) |
| Takahashi [24] | 2015 | Prospective, randomized |
TA | 40 mg | Day 0 | 100% (5/5) |
| Hanaoka [34] | 2016 | Retrospective | TA | 100 mg | Day 0 | 91.7% (11/12) |
| Miwata [45] | 2016 | Retrospective | PSL | N/A | Day 1 | 100% (6/6) |
| Hashimoto [37] | 2019 | Retrospective | TA | 40–100 mg (second: 16–50 mg) |
Day 0, 14 (two times) | 80% (4/5) |
| Oral steroid administration | ||||||
| Yamaguchi [16] | 2011 | Retrospective | PSL | 30 mg | Tapering gradually for eight weeks | 0% (0/3) |
| Isomoto [22] | 2011 | Retrospective | PSL | 30 mg | Tapering gradually for eight weeks | 50% (2/4) |
| Sato [25] | 2013 | Prospective | PSL | 30 mg | Tapering gradually for eight weeks | 100% (10/10) |
| Yamaguchi [33] | 2013 | Retrospective | PSL | 30 mg | Tapering gradually for 8–18 weeks | 27.3% (3/11) |
| Kataoka [38] | 2015 | Retrospective | PSL | 30 mg | Tapering gradually for three weeks | 33.3% (1/3) |
| Miwata [45] | 2016 | Retrospective | PSL | 0.5 mg/kg | Tapering gradually 5 mg/week | 100% (13/13) |
| Modified or hybrid steroid therapy | ||||||
| Kadota [27] | 2016 | Retrospective | TA + Oral PSL | TA: 50 mg PSL: 30 mg |
TA: Day 3, 7, 10 (three times) →Day 1 or Day 0 (once) PSL: tapering gradually for eight weeks |
71% (10/14) |
| Nagami [39] | 2016 | Retrospective | TA injection + PGA | TA: 80 mg | Day 0 | 66.7% (4/6) |
| Sakaguchi [40] | 2016 | Retrospective | TA injection + PGA | TA: 40 mg | Day 0 | 50% (1/2) |
| Iizuka [30] | 2018 | Retrospective | Oral PSL ±TA injection |
PSL: 30 mg TA: 80–120 mg |
PSL: tapering gradually for eight weeks (TA injection: Day 0) |
81.8% (9/11) |
| Oral PSL ±TA injection |
PSL: 30 mg TA: 80–120 mg |
PSL: tapering gradually for 18 weeks (TA injection: Day 0) |
36.4% (4/11) | |||
| Shibagaki [42] | 2018 | Retrospective | TA filling method | TA: 80 mg | Day 1 and Day 7 and when mild stricture was found | 0% (0/7) |
| Kadota [46] | 2020 | Retrospective | TA + Oral PSL | TA: 50 or 100 mg PSL: 30 mg |
TA: Day 0 PSL: tapering gradually for eight weeks |
61.5% (16/26) |
TA, triamcinolone acetonide; PSL, prednisolone; PGA, polyglycolic acid; N/A, not available. The dose was shown in one session. Yamaguchi and Isomoto belong to the same institution.